386 related articles for article (PubMed ID: 23806491)
21. Recent advances in understanding hormonal therapy resistant prostate cancer.
Donkena KV; Yuan H; Young CY
Curr Cancer Drug Targets; 2010 Jun; 10(4):402-10. PubMed ID: 20464780
[TBL] [Abstract][Full Text] [Related]
22. New hormonal therapies for castration-resistant prostate cancer.
Mostaghel EA; Plymate S
Endocrinol Metab Clin North Am; 2011 Sep; 40(3):625-42, x. PubMed ID: 21889725
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathways: targeting resistance in the androgen receptor for therapeutic benefit.
Mostaghel EA; Plymate SR; Montgomery B
Clin Cancer Res; 2014 Feb; 20(4):791-8. PubMed ID: 24305618
[TBL] [Abstract][Full Text] [Related]
24. [The mechanisms of prostate cancer progression through androgen receptor].
Goto Y; Sakamoto S; Ichikawa T
Nihon Rinsho; 2016 Jan; 74(1):55-9. PubMed ID: 26793880
[TBL] [Abstract][Full Text] [Related]
25. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.
Chen L; Siddiqui S; Bose S; Mooso B; Asuncion A; Bedolla RG; Vinall R; Tepper CG; Gandour-Edwards R; Shi X; Lu XH; Siddiqui J; Chinnaiyan AM; Mehra R; Devere White RW; Carraway KL; Ghosh PM
Cancer Res; 2010 Jul; 70(14):5994-6003. PubMed ID: 20587519
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
27. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
28. Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.
Reis LO
Med Oncol; 2012 Sep; 29(3):1948-55. PubMed ID: 21626233
[TBL] [Abstract][Full Text] [Related]
29. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
30. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
31. Androgen Receptor Dependence.
Chaturvedi AP; Dehm SM
Adv Exp Med Biol; 2019; 1210():333-350. PubMed ID: 31900916
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
33. [Expressions of the androgen receptor in normal prostate, benign prostatic hyperplasia and prostate cancer].
Zeng R; Liu ZY; Sun YH; Xu CL; Gao X; Jiao L
Zhonghua Nan Ke Xue; 2010 Nov; 16(11):967-72. PubMed ID: 21218636
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
[TBL] [Abstract][Full Text] [Related]
35. The androgen/androgen receptor axis in prostate cancer.
Bluemn EG; Nelson PS
Curr Opin Oncol; 2012 May; 24(3):251-7. PubMed ID: 22327838
[TBL] [Abstract][Full Text] [Related]
36. βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
Liu Z; Zhang H; Ding S; Qi S; Liu S; Sun D; Dong W; Yin L; Li M; Zhao X; Lu J
Oncol Rep; 2018 Jul; 40(1):217-225. PubMed ID: 29749458
[TBL] [Abstract][Full Text] [Related]
37. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
38. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
39. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
[TBL] [Abstract][Full Text] [Related]
40. Molecular alterations during progression of prostate cancer to androgen independence.
Saraon P; Jarvi K; Diamandis EP
Clin Chem; 2011 Oct; 57(10):1366-75. PubMed ID: 21956922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
